DIKUL - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov UL. Za polni dostop se PRIJAVITE.

1
zadetkov: 7
1.
  • Pembrolizumab versus ipilim... Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    Robert, Caroline, Prof; Ribas, Antoni, Prof; Schachter, Jacob, Prof ... The lancet oncology, 09/2019, Letnik: 20, Številka: 9
    Journal Article
    Recenzirano
    Odprti dostop

    SummaryBackgroundPembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. ...
Celotno besedilo
Dostopno za: UL
2.
  • Epacadostat plus pembrolizu... Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    Long, Georgina V, Prof; Dummer, Reinhard, Prof; Hamid, Omid, MD ... The lancet oncology, 08/2019, Letnik: 20, Številka: 8
    Journal Article
    Recenzirano

    SummaryBackgroundImmunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity ...
Celotno besedilo
Dostopno za: UL
3.
  • Binimetinib versus dacarbaz... Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
    Dummer, Reinhard, Prof; Schadendorf, Dirk, Prof; Ascierto, Paolo A, MD ... The lancet oncology, 04/2017, Letnik: 18, Številka: 4
    Journal Article
    Recenzirano

    Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor ...
Celotno besedilo
Dostopno za: UL
4.
  • Selumetinib plus dacarbazin... Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF -mutant metastatic melanoma: a phase 2 double-blind randomised study
    Robert, Caroline, Dr; Dummer, Reinhard, Prof; Gutzmer, Ralf, Prof ... The lancet oncology, 07/2013, Letnik: 14, Številka: 8
    Journal Article
    Recenzirano

    Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients ...
Celotno besedilo
Dostopno za: UL
5.
  • Dabrafenib plus trametinib ... Dabrafenib plus trametinib in patients with BRAFV600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
    Davies, Michael A, Dr; Saiag, Philippe, Prof; Robert, Caroline, Prof ... The lancet oncology, 07/2017, Letnik: 18, Številka: 7
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Dabrafenib plus trametinib improves clinical outcomes in BRAFV600 -mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not ...
Celotno besedilo
Dostopno za: UL

PDF
6.
  • Vemurafenib in patients wit... Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
    Larkin, James, Dr; Del Vecchio, Michele, MD; Ascierto, Paolo A, MD ... The lancet oncology, 04/2014, Letnik: 15, Številka: 4
    Journal Article
    Recenzirano

    Summary Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival (PFS), and overall survival in patients ...
Celotno besedilo
Dostopno za: UL
7.
  • Re-challenge with BRAF-dire... Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study
    Valpione, Sara; Carlino, Matteo S.; Mangana, Joanna ... Journal of clinical oncology, 05/2017, Letnik: 35, Številka: 15_suppl
    Journal Article
    Recenzirano

    Abstract only 9512 Background: Most patients treated with BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) eventually progress on treatment. Along with genetic acquired resistance, epigenetic ...
Celotno besedilo
Dostopno za: UL
1
zadetkov: 7

Nalaganje filtrov